This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Johan Wiström, MD; Bo Settergren, MD, PhD; Ake Gustafsson, MD, PhD; Per Juto, MD, PhD; R. S. Norrby, MD, PhD
University Hospital of Umeå Umeå, Sweden

JAMA. 1990;264(2):181-182.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

A high response rate after intradermal (ID) vaccination with the plasma-derived hepatitis B vaccine has been demonstrated in several trials.^1-3 To study the immunogenicity of a DNA-recombinant hepatitis B vaccine we initiated a controlled, randomized, open trial in which 80 healthy medical students and hospital employees who gave verbal consent were randomized to either ID vaccination in the forearm with 2 µg or intramuscular (IM) vaccination in the deltoid muscle with 10 µg of DNA-recombinant hepatitis B vaccine (Recombivax-HB, Merck Sharp & Dohme, West Point, Pa, expiration date December 1988). Vaccinations were performed by two experienced nurses at 0,1, and 6 months between December 1987 and September 1988. Hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen, and antibody to HBsAg (expressed as international units [IU/L] according to the World Health Organization standard) were analyzed by radioimmunoassay. Thirty-eight subjects (20 women and 18 men) with a mean age of 30.1 years (range, 21 to 50 years) and 37 subjects (20 women and 17 men) with a mean age of 29.4 years (range, 20 to 55 years) could be analyzed for efficacy in the ID and IM groups, respectively. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?